Somnus Therapeutics Completes Successful Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia
Links shared publicly online about this topic.
- 247total visits
Somnus Therapeutics Completes Successful Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia
Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon. The study (SOM201), condu
View full resource at medicalnewstoday.com
Tags: Sleep Disorder, Sleep, Insomnia, Insomnia Medication, Pharma, Phase 2 Clinical Trial, Sonata
Most Recently Shared on June 3, 2011 at 5:15 am By:
Somnus Therapeutics Completes Successful Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia: Somnus Therap... http://bit.ly/iwWaDa
Somnus Therapeutics Completes Successful Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia
medicalnewstoday.com — “Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has completed a Phase 2 dose-ranging study of SKP-1041, a modified-release formulation of zaleplon. The study (SOM201), condu” View full resource at medicalnewstoday.com
Most Recently Shared on June 2, 2011 at 12:06 pm By:
Somnus Therapeutics Completes Successful Phase 2 Study Of SKP-1041 For Sleep Maintenance Insomnia http://mnt.to/3WGs #sleep
Advertisement
